Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

3.91
+0.01000.26%
Post-market: 4.010.1000+2.56%19:30 EDT
Volume:243.77K
Turnover:951.98K
Market Cap:394.91M
PE:-9.09
High:4.01
Open:3.92
Low:3.84
Close:3.90
52wk High:7.13
52wk Low:2.03
Shares:101.00M
Float Shares:48.17M
Volume Ratio:0.65
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4302
EPS(LYR):-0.4847
ROE:-3727.94%
ROA:-64.18%
PB:-2.84
PE(LYR):-8.07

Loading ...

Dec 31, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 19, 2025

Major Issues Report

Form 8-K - Current report
Dec 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 08, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 08, 2025

Major Issues Report

Form 8-K - Current report
Dec 03, 2025

Major Issues Report

Form 8-K - Current report
Nov 14, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 14, 2025

Major Issues Report

Form 8-K - Current report
Nov 13, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 10, 2025

Major Issues Report

Form 8-K - Current report
Sep 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 08, 2025

Major Issues Report

Form 8-K - Current report
Aug 14, 2025

Major Issues Report

Form 8-K - Current report
Aug 14, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]